Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VRDN 
Viridian Therapeutics Inc (VRDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: VRDN (3-star) is a STRONG-BUY. BUY since 108 days. Simulated Profits (72.58%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $38.25
1 Year Target Price $38.25
| 9 | Strong Buy |
| 5 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 62.83% | Avg. Invested days 44 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.33B USD | Price to earnings Ratio - | 1Y Target Price 38.25 |
Price to earnings Ratio - | 1Y Target Price 38.25 | ||
Volume (30-day avg) 16 | Beta 0.94 | 52 Weeks Range 9.90 - 27.20 | Updated Date 11/6/2025 |
52 Weeks Range 9.90 - 27.20 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -142356% |
Management Effectiveness
Return on Assets (TTM) -39.77% | Return on Equity (TTM) -65.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1379745470 | Price to Sales(TTM) 7635.69 |
Enterprise Value 1379745470 | Price to Sales(TTM) 7635.69 | ||
Enterprise Value to Revenue 4523.76 | Enterprise Value to EBITDA -3.18 | Shares Outstanding 95367908 | Shares Floating 66944360 |
Shares Outstanding 95367908 | Shares Floating 66944360 | ||
Percent Insiders 0.16 | Percent Institutions 119.05 |
Upturn AI SWOT
Viridian Therapeutics Inc
Company Overview
History and Background
Viridian Therapeutics, Inc. (VRDN) is a biotechnology company focused on developing and commercializing novel therapies for patients suffering from serious diseases but mainly focuses on thyroid eye disease (TED). It was founded in 2012 and has evolved through various clinical trials and strategic partnerships to advance its pipeline.
Core Business Areas
- Thyroid Eye Disease (TED): Focuses on developing and commercializing therapies for Thyroid Eye Disease. Their main product candidates target the underlying mechanisms of TED to provide better treatment options for patients.
Leadership and Structure
Scott Myers is the CEO. The organizational structure includes research and development, clinical operations, commercialization, and administrative functions.
Top Products and Market Share
Key Offerings
- VRDN-001: VRDN-001 is an anti-IGF-1R monoclonal antibody being developed for Thyroid Eye Disease (TED). While specific market share data isn't currently available due to being in clinical trials, the market for TED treatments is substantial. Competitors include Tepezza (Horizon Therapeutics) which had significant revenues before the supply disruption.
- VRDN-002: VRDN-002 is a next-generation anti-IGF-1R antibody with potentially improved convenience and efficacy profile. Currently in pre-clinical/clinical trial stages and does not have market share data. Competitor is Tepezza (Horizon Therapeutics).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and intense competition. The market for TED treatments is growing due to increased awareness and the development of targeted therapies.
Positioning
Viridian Therapeutics is positioning itself as a leader in TED treatment by developing next-generation therapies that address the limitations of existing treatments.
Total Addressable Market (TAM)
The TED market is estimated to be $3-4 billion. With novel treatments and enhanced efficacy profiles, Viridian is positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Strong focus on Thyroid Eye Disease (TED)
- Novel therapeutic candidates (VRDN-001 and VRDN-002)
- Experienced leadership team
- Strong financial position due to recent capital raises
Weaknesses
- Reliance on success of clinical trials
- Limited commercial product revenue currently
- Competition from established players (Horizon)
- High R&D expenditure
Opportunities
- Successful clinical trial outcomes for VRDN-001 and VRDN-002
- Expansion into new indications beyond TED
- Strategic partnerships for commercialization
- Potential for orphan drug designation
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from biosimilars
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- HZNP
- ALNY
- MRTX
Competitive Landscape
Viridian faces competition from established companies like Horizon Therapeutics and other emerging biotech companies. Viridian's advantage lies in its novel therapeutic candidates and focus on improving upon existing treatments for TED.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of clinical trials and expansion of the product pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary but generally anticipate revenue generation beginning in the next few years.
Recent Initiatives: Recent initiatives include the advancement of VRDN-001 and VRDN-002 through clinical trials, and strategic financing activities to support ongoing research and development.
Summary
Viridian Therapeutics is a biotechnology company focused on developing novel therapies for Thyroid Eye Disease. The company's financial health is strong, backed by its recent finances. Viridian's future growth hinges on the success of its clinical trials. A major risk is the potential for competition from larger, more established pharmaceutical companies and potential setbacks in regulatory approval and clinical trials. While currently unprofitable, successful clinical trials could drastically alter the company's future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Viridian Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2014-06-18 | CEO, President & Director Mr. Stephen F. Mahoney J.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 143 | |
Full time employees 143 | |||
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.